Clinical trialNo phase (not a drug trial)Recruiting
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism
- Outcome
- Ongoing
- Phase
- No phase (not a drug trial)
- Status
- Recruiting
- Study type
- Interventional
- Start
- 30 January 2026
- Expected end
- 30 January 2030
- Enrollment
- 259 participants
- Sites
- 8
- Primary outcomes
- Cumulative incidence of recurrent Venous Thromboembolism/VTE
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 9 November 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.